08/11 Taiwan BIO Weekly
2025-08-11 |
| Taiwan BIO Weekly |
| PharmaEssentia joins forces with the Development Center for Biotechnology to develop new immunotherapy Press release 8 August, 2025 PharmaEssentia (TW: 6446) is expanding into the development of new immunotherapy cancer drugs with its announcement that it will in-licence the novel CD73 inhibitor antibody drug, DCBPR2201 from Taiwan's Development Center for Biotechnology (DCB). The company aims to make this its second growth engine following its blood cancer drug. PharmaEssentia noted that this collaboration could leverage the company’s technologies in antibody-drug conjugates (ADC) and bispecific antibodies to further combine DCBPR2201 with PharmaEssentia’s existing drugs, advancing Taiwan’s position in the immunotherapy market to a new level. More... (in Chinese) |
| Andros Pharmaceuticals and Yung Shin Pharmaceutical Industrial form strategic alliance to target rosacea 7 August, 2025 Andros Pharmaceuticals (TW: 6917) announced that it has partnered with Yung Shin Pharmaceutical Industrial (TW: 3705) to co-develop and license a high-value, high-margin niche generic drug for rosacea, currently without a local equivalent in Taiwan. Andros will oversee development and manufacturing, including formulation design, analytical methods, GMP processes, and in vitro testing, while Yung Shin will manage regulatory approvals, drug registration, and future marketing and sales. The collaboration will first target the Taiwan market, with plans for international expansion. More... (in Chinese) |
| Senhwa Biosciences receives NCI funding for MYC-abnormal lymphoma drug, submits IND application to FDA 7 August, 2025 Senhwa Biosciences (TW: 6492) announced that its investigational drug Pidnarulex (CX-5461) has been selected for a five-year cancer program sponsored by the US National Cancer Institute (NCI). Following the launch of its first monotherapy trial for advanced solid tumors, the company has also submitted an IND application to the US FDA for a Phase 1b/2 trial targeting B-cell lymphoma with MYC gene abnormalities, marking a key milestone in CX-5461’s development. MYC is a critical oncogene, altered in about 28 percent of cancers, including lung, breast, liver cancers, and lymphomas, driving tumor growth through cell proliferation, angiogenesis, and apoptosis suppression. CX-5461 is designed to stabilize G-4 quadruplex structures in cancer cell DNA, inhibiting MYC expression and effectively blocking tumor growth pathways. More... (in Chinese) |
| US, Japan, and Taiwan Experts Gather at NUWA Forum -- Over 200 Reproductive Specialists Explore the Future of Integrated Fertility Technology Press release 6 August, 2025 Preimplantation Genetic Testing for Aneuploidy (PGT-A), a screening method used during IVF to assess embryo chromosomal health, has gained widespread adoption in reproductive medicine worldwide. Yet the accuracy of various PGT-A platforms and their true clinical value remain points of ongoing debate. To dive deeper into the science behind PGT-A and explore the latest validated technologies, NUWA Fertility partnered with the Institute of Biotechnology at National Taiwan University to host its annual Reproductive Medicine Forum on August 3. The event welcomed over 200 fertility professionals and representatives from more than 65 reproductive centers, drawing international experts from the U.S. and Japan for a day of lively discussion and data-driven insights. More... |
| From AI to Precision Medicine: Taiwan's Smart Healthcare Innovations Shine at Taiwan Expo USA 2025 Press release 6 August, 2025 The Smart Healthcare Pavilion at Taiwan Expo USA 2025 will take place at the Kay Bailey Hutchison Convention Center in Dallas, Texas, from August 14 to 16. Featuring two world-leading hospitals and eight cutting-edge companies, the pavilion highlights Taiwan’s exceptional strengths in telemedicine, AI-driven solutions, and precision medicine. More... |
| Acer Medical's medical software now used in over 500 healthcare institutions worldwide 6 August, 2025 Acer Medical (TW: 6857) announced that its AI medical software has been adopted by over 500 healthcare institutions worldwide, spanning Taiwan, Japan, Southeast Asia, Central America, and Europe. The company’s portfolio, including AI tools for diabetic retinopathy (VeriSee DR), age-related macular degeneration (VeriSee AMD), and abnormal bone density screening (VeriOsteo OP), has secured multi-country medical approvals and is designed for integration into existing hospital systems with mobile support. According to the company, these solutions enhance examination efficiency, reduce manpower needs, and speed up clinical decision-making, a reflection of the company's expertise in AI-driven healthcare and the growing global demand for smart medical technologies. More... (in Chinese) |
| SciVision Biotech applies for drug registration of its intra-articular injectable product in China 5 August, 2025 SciVision Biotech (TW: 1786) announced that it has signed an agreement with China Shenghuo Pharmaceutical, a subsidiary of the well-known Chinese pharmaceutical conglomerate CR Sanjiu under China Resources Group. China Shenghuo Pharmaceutical will assist SciVision in obtaining drug registration in China for its intra-articular injection product. The application process is currently underway. Once the drug registration is approved, SciVision is expected to secure an annual order of 2 million doses of its intra-articular injection, which could conservatively contribute over NT$2 billion in annual revenue with a gross margin exceeding 50 percent. More... (in Chinese) |
| MegaPro Biomedical makes developmental headway, plans to file for IPO next year 5 August, 2025 MegaPro Biomedical (TW: 6827) in a recent media briefing stated that it is focusing on cancer imaging diagnostics and therapeutics, and has been developing an MRI contrast agent for liver cancer cell detection and a new formulation drug for prostate cancer. The company also aims to apply for new drug approvals for both a new chemical entity and a reformulated drug by 2028. Critical clinical trials for both products are set to begin by the end of this year and early next year, with plans to apply for an IPO (Initial Public Offering) in 2025. More... (in Chinese) |
| This Taiwanese hospital has reduced ICU mortality using AIoT 4 August, 2025 An integrated AI, telemedicine, and Internet of Things system for the ICU has brought down the overall mortality rate in critical care at China University Medical Hospital in Taiwan. At HIMSS25 APAC, Dr Wen-Sheng Feng, director of the Digital Transformation Technology Office at CMUH, presented how they started building a scalable AI-powered system in the ICU and how it works. More... |
| EirGenix Expands Phase III Trial of Biosimilar EG1206A to Poland and Greece 4 August, 2025 EirGenix (TW: 6589) recently announced that it has submitted Phase III clinical trial applications for its pertuzumab biosimilar, EG1206A, to Poland and Greece via the EU Clinical Trials Information System. This move further expands its multinational, multicenter clinical trial footprint. According to the company, EG1206A is primarily intended for the treatment of HER2-positive early-stage and metastatic breast cancer. More... (in Chinese) |
| AnBogen Therapeutics’ ABT-301 triple therapy receives FDA approval to initiate Phase I/II clinical trial for advanced colorectal cancer 4 August, 2025 AnBogen Therapeutics announced that its investigational small-molecule drug ABT-301, combined with the immune checkpoint inhibitor tislelizumab and the anti-angiogenesis inhibitor bevacizumab as a triple therapy, has received US FDA approval for its IND application. This approval allows the initiation of a Phase I/II clinical trial for treating advanced metastatic colorectal cancer (mCRC). More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |